Cancer survival depends on the health-care system available to the patients [18], including an effective diagnosis and treatment in routine clinical practice [6]. In Europe, health-care systems and cancer therapy are mostly established in the public sector, which aims for an equal access to med...
Because I do value those deep molecular responses. You know, sometimes there’s the argument that, well, they don’t improve survival. Well, no, you know, with imatinib you’ve already reached near normal life expectancy, so, now we’re looking beyond just the survival benefit. And so, ...
In CML, BCR-ABL phosphorylates Signal Transducer and Activator of Transcription 5 (STAT5), promoting cell survival and differentiation [9]. However, upon TKI-treatment, persistent cells have increased STAT3 activation [10, 11]. Genetic deletion of STAT3 with BCR-ABL overexpression impairs colony fo...
The 8-year survival for patients with a CCI ≥5 was 48%, compared with 91% for those with a CCI of 2.8 Thus, the presence of comorbidities is an important element of the management of patients with CML. The patient Our patient is a 59-year-old construction worker with an 8.5 pack-...
Patients treated with combination therapy had improved long-term survival in our cohort, and it appears that the etiology of this benefit primarily arose from a higher rate of patients proceeding to ASCT (32.5% with IC/HMA + TKI vs. 10.7% with TKI alone). Among patients who had a cli...
Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients Article Open access 26 November 2020 The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free...
We analyzed overall survival in the 87 patients with known outcome according to sex, age, CML duration, type of CML treatment, line of TKI therapy, history of smoking, comorbidities, TKI interruption due to COVID-19, administration of any treatment against COVID-19 (antimicrobial agents, ...
Aim To analyze the impact of first-line treatment duration with imatinib and 2G TKI on molecular relapse-free survival (MRFS) in CML pts with sustained DMR. Patients and methods In total, 174 CML pts in chronic phase with ≥3 years treatment duration and sustained DMR (MR4-MR5, BCR-ABL ...
In summary, CML-RAE-1γ-Dex were demonstrated to simultaneously activate multiple immune cell types such as NK cells and CD4+and CD8+T lymphocytes, through the NKG2D/NKG2D-L (RAE-1γ) pathway, which led to anti-CML efficacy in vitro and in vivo. The survival time of leukemia-bearing mic...
Event-free survival (EFS) was measured from the start of treatment to the date of any of the following events while on therapy: loss of complete hematologic remission, loss of major cytogenetic response (MCyR), progression to accelerated (defined as blasts ≥15%, blasts + promyelocytes≥30%...